Global Eye Stent Market Size By Type (Polymer, Gelatin), By Application (Eye Clinics, Eye Research Institutes), By Region, And Segment Forecasts, 2023 to 2032

The Global Eye Stent Market was valued at USD 912 million in 2023 and is projected to reach USD 1.76 billion by 2031, growing at a CAGR of 8.6% during the forecast period from 2023 to 2031. The eye stent market is experiencing significant growth due to the rising prevalence of glaucoma, increasing aging population, and advancements in minimally invasive glaucoma surgery (MIGS) technologies. Eye stents, often used during MIGS, help to reduce intraocular pressure by facilitating aqueous humor drainage, proving to be a safer alternative to traditional procedures.

Drivers:

1. Rising Prevalence of Glaucoma:

Glaucoma, a leading cause of irreversible blindness worldwide, is on the rise. With an aging population, the incidence is expected to grow, driving demand for effective treatment options like eye stents.

2. Advancements in Minimally Invasive Procedures:

The preference for MIGS over traditional surgeries due to lower complication rates and quicker recovery is accelerating the adoption of eye stents. Continuous innovations in design and materials are improving surgical outcomes.

3. Increased Awareness and Early Diagnosis:

Public health initiatives and improved screening methods are leading to earlier glaucoma diagnoses, boosting the demand for early-stage interventions such as stent implantation.

Restraints:

1. High Cost of Treatment and Devices:

The cost of eye stents and MIGS procedures remains high, particularly in developing regions, limiting widespread access and adoption.

2. Limited Reimbursement Coverage:

In several countries, reimbursement policies for MIGS and eye stents are not fully developed, creating barriers for both patients and healthcare providers.

Opportunity:

1. Expansion in Emerging Markets:

With growing healthcare infrastructure and increasing ophthalmologic awareness in Asia-Pacific and Latin America, these regions present untapped potential for eye stent manufacturers.

2. Technological Innovations in Stent Materials:

Ongoing R&D focused on biocompatible materials and next-generation stent designs is expected to improve safety, efficacy, and adoption across a wider patient base.

3. Collaborations and Strategic Partnerships:

Collaborations between ophthalmic device manufacturers, hospitals, and research institutions can foster innovation and accelerate market penetration.

Market by System Type Insights:

The Single Stent Systems segment held the largest market share in 2023. These systems are widely preferred due to their simplicity and lower cost compared to multiple stent configurations. However, the Multiple Stent Systems segment is expected to grow rapidly during the forecast period due to their increased effectiveness in lowering intraocular pressure in advanced cases.

Market by End-use Insights:

Hospitals and Ambulatory Surgical Centers (ASCs) dominated the market in 2023. ASCs are gaining traction due to their cost-effectiveness, faster procedures, and growing patient preference for outpatient care. The adoption of eye stents in specialized ophthalmology clinics is also expected to rise significantly as expertise and awareness grow.

Market by Regional Insights:

North America led the market in 2023, driven by advanced healthcare infrastructure, a high rate of glaucoma diagnosis, and the strong presence of key players. Asia-Pacific is projected to register the highest CAGR during the forecast period due to a large patient pool, increasing healthcare spending, and rising awareness in countries like India and China.

Competitive Scenario:

Key players in the Global Eye Stent Market include Glaukos Corporation, Ivantis Inc. (acquired by Alcon), Santen Pharmaceutical Co., Ltd., Allergan (AbbVie), iStar Medical, and Sight Sciences. These companies are focusing on innovation, regulatory approvals, and expanding their global footprint through partnerships and acquisitions.

Scope of Work – Global Eye Stent Market

Report Metric Details

Market Size (2023) USD 912 million

Projected Market Size (2031) USD 1.76 billion

CAGR (2023–2031) 8.6%

Market Segments By System Type, End-use, Region

Growth Drivers Rise in glaucoma cases, MIGS adoption

Opportunities Emerging markets, new stent materials

Key Market Developments:

2023: Glaukos Corporation received FDA approval for its next-generation iStent Infinite, designed for use in patients undergoing cataract surgery.

2024: Alcon completed the integration of Ivantis, enhancing its MIGS product portfolio with Hydrus Microstent.

2025: Santen Pharmaceutical launched a new MIGS-compatible stent in Japan and Europe, focusing on improved flexibility and reduced implantation time.

FAQs:

1) What is the current market size of the Global Eye Stent Market?

The market was valued at USD 912 million in 2023.

2) What is the major growth driver of the Global Eye Stent Market?

The primary driver is the rising prevalence of glaucoma and increased adoption of minimally invasive glaucoma surgeries.

3) Which is the largest region during the forecast period in the Global Eye Stent Market?

North America is projected to remain the largest region due to advanced healthcare infrastructure and high diagnosis rates.

4) Which segment accounted for the largest market share in the Global Eye Stent Market?

The Single Stent Systems segment held the largest share in 2023.

5) Who are the key market players in the Global Eye Stent Market?

Key players include Glaukos Corporation, Alcon, Allergan (AbbVie), Santen Pharmaceutical, and iStar Medical.